MEET OUR EXPERTS
Leading an evolution in neurology diagnostics
Mayo Clinic neurologists will be available April 19–22 at booth 5018 from noon to 1PM. Stop by to meet the experts who designed and implemented this testing.
Clinically backed neurology and neurogenetics testing
Powered by expertise from our research labs, clinical labs, and clinical practice, Mayo Clinic Laboratories has developed panels customized to address specific autoimmune neurology and neurogenetic phenotypes. For patients with neurologic conditions, this testing can provide life-changing answers.
Connect with us at the American Academy of Neurology Annual Meeting to learn how our evaluations can inform your clinical practice. Drop by to talk to one of our experts about:
- Why our evaluations are at the leading edge of testing.
- Our collaborative approach to test development.
- The impact our testing has on patient care.
ExPERTs schedule
| Date & Time | Neuroimmunology | Behavioral Neurology | Muscle & Nerve |
|---|---|---|---|
| Sunday, April 19th from 12 - 1PM | Christopher Klein, M.D. & Eoin Flanagan, M.B., B.Ch. | Stuart McCarter, M.D. | Margherita Milone, M.D., Ph.D. |
| Monday, April 20th from 12 - 1PM | Divyanshu Dubey, M.B.B.S. & Anastasia Zekeridou, M.D., Ph.D. | Ronald Petersen, M.D., Ph.D. | Sarah Berini, M.D. |
| Tuesday, April 21st from 12 - 1PM | Sean Pittock, M.D. | Vijay Ramanan, M.D., Ph.D. & Jonathan Graff-Radford, M.D. | Visit with Mayo Clinic Laboratories’ representatives during this time. |
| Wednesday, April 22nd from 12 - 1PM | Visit with Mayo Clinic Laboratories’ representatives during this time. | Visit with Mayo Clinic Laboratories’ representatives during this time. | Visit with Mayo Clinic Laboratories’ representatives during this time. |
Highlights
Discover how Mayo Clinic’s nationally recognized Muscle Pathology Laboratory provides unparalleled diagnostic accuracy for rare muscle diseases through decades of experience, specialized testing, and integrated clinical-pathological evaluation.
Learn how our autoimmune/paraneoplastic evaluation for encephalopathy uses CSF testing to confirm an autoimmune GFAP meningoencephalomyelitis diagnosis.
Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.
Learn more about our CNS demyelinating disease testing through this case study focused on MOG-IgG as a marker of acute disseminated encephalomyelitis.
Mayo Clinic Laboratories’ MS testing cascade, which starts with kappa free light chain (KFLC) testing and reflexes to oligoclonal banding when indicated, is supported by the revised 2024 McDonald Criteria. This approach delivers faster, more definitive results, enabling earlier treatment decisions and improved patient outcomes.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent examples of diagnostic innovations that are improving patient care. Dr. Pritt also welcomes Matthew Schultz, Ph.D., a clinical biochemical geneticist at Mayo Clinic, to discuss how a novel test is delivering answers for patients with a recently identified peripheral neuropathy.
This presentation offers a clear introduction to emerging blood based biomarkers for Alzheimer’s disease.
In this video, Dr. Vijay Ramanan shares perspectives on rational approaches to testing in the cognitive neurology, mild cognitive impairment, and dementia settings.
SAAmplify™-αSYN testing offers unprecedented accuracy in diagnosing Parkinson’s and Lewy body dementia.
After months of misdiagnoses, Tom Heisler found answers at Mayo Clinic, where advanced renal pathology revealed IgG4-related disease and led to his recovery.
Join us for a webinar exploring the revolutionary way SAAmplify™–αSYN testing, which is offered by Mayo Clinic Laboratories in collaboration with Amprion, is improving diagnostic accuracy for patients with neurodegenerative disorders.
Diagnostic advances allow earlier & more accurate detection of Alzheimer's using cerebrospinal fluid biomarkers.